Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accounts Payables: 2022-2025

Historic Accounts Payables for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • Corvus Pharmaceuticals' Accounts Payables rose 5.39% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 5.39%. This contributed to the annual value of $2.6 million for FY2024, which is 69.31% up from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Accounts Payables of $2.0 million as of Q3 2025, which was down 37.07% from $3.1 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Accounts Payables peaked at $4.2 million during Q3 2022, and registered a low of $1.2 million during Q2 2024.
  • Moreover, its 3-year median value for Accounts Payables was $1.6 million (2024), whereas its average is $1.8 million.
  • In the last 5 years, Corvus Pharmaceuticals' Accounts Payables slumped by 66.78% in 2023 and then skyrocketed by 158.62% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Accounts Payables (Quarterly) stood at $2.0 million in 2022, then decreased by 22.82% to $1.5 million in 2023, then spiked by 69.31% to $2.6 million in 2024, then increased by 5.39% to $2.0 million in 2025.
  • Its Accounts Payables was $2.0 million in Q3 2025, compared to $3.1 million in Q2 2025 and $1.3 million in Q1 2025.